Breast and axillary surgery planning Multidisciplinary review of breast and axillary local treatment. | Local care Care pathway | nci |
Postoperative radiation review Review breast, chest wall and nodal radiation needs with the local team. | Local care Care pathway | nci |
Adjuvant endocrine treatment Confirm endocrine agent, menopausal physiology and ovarian suppression where appropriate. | Endocrine therapy Care pathway | nci |
Preoperative aromatase inhibitor review Consider endocrine downstaging in a selected postmenopausal patient. | Endocrine therapy Care pathway | nci |
Early chemotherapy review Choose a regimen after recurrence-risk, comorbidity and genomic-assay review where applicable. | Chemotherapy Care pathway | nci |
Abemaciclib plus adjuvant endocrine therapy High-risk node-positive disease under the revised monarchE label. | Adjuvant targeted therapy FDA-approved | abema, abema_label, verzenio_coverage_20261109 |
Ribociclib plus adjuvant aromatase inhibitor Stage II or III high-risk disease after explicit NATALEE risk review. | Adjuvant targeted therapy FDA-approved | ribo_adj, ribo_label, kisqali_coverage_20261109 |
Adjuvant olaparib Germline BRCA-associated high-risk disease after chemotherapy and definitive local care. | Adjuvant targeted therapy FDA-approved | olaparib |
T-DXd followed by taxane, trastuzumab and pertuzumab Newly approved neoadjuvant sequence for HER2-positive stage II–III disease. | Neoadjuvant HER2 therapy FDA-approved | tdxd_early, enhertu |
Trastuzumab, pertuzumab and chemotherapy before surgery HER2-positive disease meeting tumor-size or nodal criteria. | Neoadjuvant HER2 therapy FDA-approved | perjeta |
Trastuzumab, pertuzumab and adjuvant chemotherapy review Review a HER2-directed adjuvant course for high-risk disease. | Adjuvant HER2 therapy FDA-approved | perjeta |
T-DXd after residual invasive HER2-positive disease Adjuvant T-DXd after trastuzumab and taxane-based neoadjuvant treatment. | Post-neoadjuvant HER2 therapy FDA-approved | tdxd_early, enhertu |
Pembrolizumab with chemotherapy, then postoperative pembrolizumab Review the complete KEYNOTE-522 perioperative course. | Perioperative TNBC therapy FDA-approved | kn522_label, kn522, kn522_os |
Complete planned postoperative pembrolizumab Continuation of an established perioperative regimen after surgery. | Post-neoadjuvant TNBC therapy FDA-approved | kn522_label |
Adjuvant capecitabine for residual TNBC Evidence-supported off-label review after residual disease following chemotherapy. | Post-neoadjuvant chemotherapy Evidence-supported off-label | createx, dpyd |
Ribociclib plus an aromatase inhibitor Initial endocrine-based option with appropriate gonadal suppression. | Initial endocrine-based therapy FDA-approved | ribo_label, kisqali_coverage_20261109 |
Inavolisib, palbociclib and fulvestrant Endocrine-resistant PIK3CA-mutated recurrence after adjuvant endocrine therapy. | PI3K-directed therapy FDA-approved | inavo, inavo_label |
Capivasertib plus fulvestrant Alteration-directed option after progression on at least one endocrine-based regimen in the metastatic setting, or recurrence on or within 12 months of completing adjuvant therapy. | AKT-directed therapy FDA-approved | capi, capi_label, capi_label_i9 |
Elacestrant Oral endocrine option in the labeled adult male or postmenopausal population. | ESR1-directed endocrine therapy FDA-approved | elacestrant, elacestrant_label |
Vepdegestrant Approved oral estrogen-receptor degrader after endocrine progression. | ESR1-directed endocrine therapy FDA-approved | vep, vep_label |
Imlunestrant plus abemaciclib Endocrine/CDK4/6 combination after qualifying progression. | ESR1-directed combination FDA-approved | imlu_abema, imlu_label |
Camizestrant plus the ongoing CDK4/6 inhibitor Accelerated approval: switch the endocrine partner upon ESR1 detection before clinical progression; confirmatory clinical benefit remains pending. | On-treatment molecular switch FDA accelerated approval | cami, cami_label |
Gedatolisib, fulvestrant and palbociclib Option when a reviewed test detects no PIK3CA mutation, after progression on or after at least one line of endocrine therapy in the metastatic setting. | PI3K/mTOR-directed therapy FDA-approved | geda, geda_label |
Gedatolisib and fulvestrant Option when a reviewed test detects no PIK3CA mutation, after progression on or after at least one line of endocrine therapy in the metastatic setting. | PI3K/mTOR-directed therapy FDA-approved | geda, geda_label |
T-DXd after endocrine progression in HER2-low or ultralow disease Separate low and ultralow pathology from IHC 0 without staining. | Antibody-drug conjugate FDA-approved | tdxd_low, enhertu |
Datopotamab deruxtecan after endocrine therapy and advanced chemotherapy Prior endocrine-based and advanced chemotherapy must be documented. | Antibody-drug conjugate FDA-approved | dato_hr, dato_label |
Sacituzumab govitecan after multiple HR-positive therapies Later-line endocrine-treated disease after the defined exposure review. | Antibody-drug conjugate FDA-approved | sg_hr, sg_label, trodelvy_coverage_20261109 |
Olaparib for germline BRCA-associated metastatic disease Review germline result, prior chemotherapy and endocrine history. | PARP inhibitor FDA-approved | olaparib |
T-DXd plus pertuzumab first line First-line HER2-positive option in the approved setting. | Initial HER2 therapy FDA-approved | tdxd_first, enhertu |
Taxane, trastuzumab and pertuzumab first line Established HER2-directed chemotherapy option. | Initial HER2 therapy FDA-approved | perjeta, tdxd_first |
Palbociclib plus HER2-directed and endocrine maintenance After nonprogressing taxane/HER2 induction in HR-positive disease. | HER2 maintenance FDA-approved | palbo_maint, palbo_label |
Tucatinib plus trastuzumab and pertuzumab maintenance Maintenance following nonprogressing THP induction. | HER2 maintenance FDA-approved | tuca_maint, tuca_label |
T-DXd after prior HER2 therapy HER2-positive disease after the label-defined prior regimen. | Subsequent HER2 therapy FDA-approved | enhertu, destiny-breast02 |
Tucatinib, trastuzumab and capecitabine Option after prior metastatic HER2 therapy, including selected patients with brain metastases. | Subsequent HER2 therapy FDA-approved | tuca_later, dpyd, tuca_label, capecitabine_i8 |
Pembrolizumab plus chemotherapy for PD-L1-positive TNBC PD-L1 CPS-selected initial advanced TNBC option. | Initial TNBC therapy FDA-approved | kn355, kn522_label |
Sacituzumab govitecan plus pembrolizumab first line New first-line option for PD-L1 CPS-selected TNBC. | Initial TNBC therapy FDA-approved | sg_first, sg_label |
Sacituzumab govitecan first line without checkpoint therapy Requires an explicit clinician finding that checkpoint therapy is unsuitable. | Initial TNBC therapy FDA-approved | sg_first, sg_label, trodelvy_coverage_20261109 |
Datopotamab deruxtecan for checkpoint-ineligible TNBC The TNBC label is not restricted to first line. Prior treatment or ADC exposure requires a separate evidence review; TROPION-Breast02 studied untreated advanced disease. | TNBC therapy with source-qualified discussion FDA-approved | dato_tnbc, dato_label |
T-DXd for HER2-low disease after chemotherapy HER2-low disease after qualifying chemotherapy or early recurrence. | Antibody-drug conjugate FDA-approved | enhertu |
T-DM1 after residual invasive HER2-positive disease Established adjuvant HER2 option after residual disease following taxane and trastuzumab. | Post-neoadjuvant HER2 therapy FDA-approved | tdm1, tdxd_early, kadcyla_coverage_20261109 |
Imlunestrant Oral endocrine monotherapy after progression in ESR1-mutated disease. | ESR1-directed endocrine monotherapy FDA-approved | imlu, imlu_label |
Adjuvant trastuzumab-based treatment review Select postoperative HER2-directed care using tumor size, nodes and comorbidities. | Adjuvant HER2 therapy Care pathway | nci, perjeta |
Adjuvant paclitaxel and trastuzumab for small node-negative tumors Review the less-intensive APT regimen for documented small node-negative HER2-positive disease. | Adjuvant HER2 therapy Source-supported regimen review | apt, nci, apt_initial |
Sacituzumab govitecan after prior triple-negative therapies Review after at least two prior systemic therapies, including at least one for metastatic disease. | Antibody-drug conjugate FDA-approved | sg_label, trodelvy_coverage_20261109 |
Alpelisib plus fulvestrant The adult label permits use after progression on an endocrine-based regimen with a confirmed PIK3CA alteration. SOLAR-1 numerical applicability separately requires its AI-progressed, postmenopausal/male population. | PI3K-directed therapy FDA-approved | alpelisib_label |
Ribociclib plus fulvestrant Adult HR-positive/HER2-negative advanced or metastatic disease; initial endocrine-based treatment or progression on endocrine treatment. Appropriate gonadal suppression and patient safety review. | Source-supported additional alternative FDA-approved | kisqali, monaleesa3_updated |
Abemaciclib plus fulvestrant Adult HR-positive/HER2-negative advanced/metastatic disease with progression following endocrine treatment; gonadal suppression when indicated. | Source-supported additional alternative FDA-approved | verzenio, monarch2_os |
Palbociclib plus fulvestrant Adult HR-positive/HER2-negative advanced/metastatic disease progressing following endocrine treatment; appropriate gonadal suppression. | Source-supported additional alternative FDA-approved | ibrance, paloma3_primary |
HER2-directed and endocrine maintenance without added escalation Not a new standalone approval claim. Source-supported standard-control pathway after nonprogressing HER2-directed induction in HR-positive/HER2-positive advanced disease, with a reviewed endocrine partner and appropriate suppression. | Source-supported additional alternative Source-supported maintenance pathway; no standalone approval claim | ibrance, patina_registry, patina_primary |
Everolimus plus exemestane Postmenopausal women with advanced HR-positive/HER2-negative disease after failure of letrozole or anastrozole. Do not substitute generic AI exposure or silently generalize to males/premenopausal patients. | Source-supported additional alternative FDA-approved | afinitor, bolero2_os |
Talazoparib for germline BRCA-associated advanced disease Adult deleterious/suspected deleterious germlineBRCA-mutated HER2-negative locally advanced/metastatic disease with therapy-specific authorized companion test. Do not import olaparib's chemotherapy/endocrine prerequisites into this label. | Source-supported additional alternative FDA-approved | talzenna, embraca_final |
Abemaciclib plus an aromatase inhibitor Initial endocrine-based option in adult HR-positive/HER2-negative advanced disease with appropriate gonadal suppression. | Initial endocrine-based alternative FDA-approved | verzenio_coverage_20261109 |
Palbociclib plus an aromatase inhibitor Initial endocrine-based option in adult HR-positive/HER2-negative advanced disease with appropriate gonadal suppression. | Initial endocrine-based alternative FDA-approved | ibrance_coverage_20261109 |
Capecitabine monotherapy for advanced breast cancer Single-agent review when anthracycline- or taxane-containing chemotherapy is not indicated. | Conventional chemotherapy alternative FDA-approved within reviewed label context | capecitabine_i8 |
Eribulin for previously treated metastatic breast cancer Label use requires at least two prior metastatic chemotherapy regimens and prior anthracycline plus taxane in adjuvant or metastatic treatment. | Conventional chemotherapy alternative FDA-approved within reviewed label context | eribulin_i8 |
T-DM1 (ado-trastuzumab emtansine) after trastuzumab and a taxane Single-agent option for metastatic HER2-positive disease after trastuzumab and a taxane, given for metastatic disease or with recurrence during or within six months of adjuvant treatment. | Subsequent HER2 therapy FDA-approved | tdm1 |
Neratinib plus capecitabine after two or more anti-HER2 regimens for metastatic disease Oral combination for advanced or metastatic HER2-positive disease after two or more anti-HER2 regimens given for metastatic disease. | Subsequent HER2 therapy FDA-approved | nerlynx_label, dpyd |
Extended adjuvant neratinib after trastuzumab-based treatment One year of oral treatment that follows completed adjuvant trastuzumab-based treatment in early HER2-positive disease. | Adjuvant HER2 therapy FDA-approved | nerlynx_label |
Gemcitabine plus paclitaxel, first line after adjuvant anthracycline First-line chemotherapy combination for metastatic disease after adjuvant anthracycline chemotherapy, or when an anthracycline was contraindicated. | Conventional chemotherapy alternative FDA-approved | gemcitabine_label |
Albumin-bound paclitaxel after earlier chemotherapy Single-agent taxane after combination chemotherapy for metastatic disease has failed, or after relapse within 6 months of adjuvant chemotherapy. | Conventional chemotherapy alternative FDA-approved | abraxane_label |
Carboplatin for germline BRCA-associated advanced triple-negative disease (off-label) Off-label single-agent platinum for advanced triple-negative disease with a germline BRCA1 or BRCA2 pathogenic variant, supported by the TNT trial. | Conventional chemotherapy alternative Evidence-supported off-label | tnt_2018, carboplatin_label |
Switch to fulvestrant with continued palbociclib (off-label) Off-label switch from the aromatase inhibitor to fulvestrant, keeping palbociclib, when an ESR1 mutation appears in blood without disease progression; supported by the PADA-1 trial. | On-treatment molecular switch Evidence-supported off-label | pada1_2022, faslodex_label |
Adjuvant T-DM1 for stage I HER2-positive disease (off-label) Off-label one-year T-DM1 course after surgery for stage I HER2-positive disease, supported by the ATEMPT trial. | Adjuvant HER2 therapy Evidence-supported off-label | atempt_2021, nci_pdq_breast_20250425, tdm1, registry_NCT01853748 |
Docetaxel, carboplatin, trastuzumab and pertuzumab before surgery (TCHP) Six preoperative every-3-week cycles of pertuzumab, trastuzumab, docetaxel (75 mg/m2) and carboplatin (AUC 6) without anthracycline. | Neoadjuvant HER2 therapy FDA-approved | perjeta, herceptin_label, docetaxel_label, carboplatin_label |